Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Key Takeaways

• Tempus Preview delivers preliminary biomarker insights within 24 hours of sample receipt
• Focuses on MSI‑H, EGFR mutations, and FGFR fusions in key cancers
• Powered by Paige Predict AI, trained on millions of H&E slides
• Early insights aim to shorten treatment decision time and improve outcomes

Pulse Analysis

Precision oncology has long wrestled with a timing paradox: clinicians need detailed molecular data to tailor therapies, yet comprehensive sequencing can take weeks. The delay forces oncologists to make initial treatment choices in an informational vacuum, often defaulting to broader regimens that may be suboptimal. Tempus, leveraging its extensive multimodal data repository and integrated lab infrastructure, is attempting to rewrite that narrative. By embedding AI‑driven analytics at the earliest laboratory touchpoint, the company seeks to compress the diagnostic timeline and deliver actionable insights when they matter most.

Tempus Preview’s first rollout zeroes in on three high‑value biomarkers—microsatellite instability‑high (MSI‑H), EGFR mutations in non‑small cell lung cancer, and rare FGFR fusions in hepatobiliary and bladder tumors. Using Paige Predict, an AI model trained on millions of hematoxylin‑eosin slides, the platform predicts the likelihood of these alterations from routine pathology images. The result is a rapid, preliminary report that can flag patients likely to benefit from immune checkpoint inhibitors, targeted EGFR therapies, or FGFR‑directed agents, well before the full genomic panel returns. This early flagging can streamline enrollment in clinical trials and guide interim therapeutic decisions.

The broader market implications are significant. As payers and providers demand faster, cost‑effective decision support, tools that shorten the diagnostic lag could become a differentiator for labs and tech firms alike. Tempus’s hybrid model—combining a CLIA‑certified lab with a proprietary AI platform—creates a data flywheel that may accelerate model refinement and expand the biomarker suite. Competitors will need comparable speed and accuracy to stay relevant, while regulators will watch closely as AI‑derived predictions move closer to clinical decision‑making. If adoption scales, Tempus Preview could set a new benchmark for real‑time precision medicine.